The impact of immune cells selection on the therapeutic efficacy of CAR-T cell therapy
10.3760/cma.j.cn121090-20240321-00104
- VernacularTitle:肿瘤免疫疗法中细胞来源对治疗效果的影响
- Author:
Wenxin QI
1
;
Weilong ZHANG
;
Hongmei JING
Author Information
1. 北京大学第三医院血液科，北京 100191
- From:
Chinese Journal of Hematology
2024;45(7):699-704
- CountryChina
- Language:Chinese
-
Abstract:
Here we summarized novel Chimeric antigen receptor T-cell immunotherapy (CAR-T) based on the immune material aspect. Young healthy donor T cells, stem cell-like memory T cells, human induced pluripotent stem cells and umbilical cord blood T cells are all potential candidates to enhance CAR-T cell therapy depending on their anti-tumor efficacy. Besides, due to less restricted major histocompatibility complex (MHC) mismatch effect, viral specific T cells, γδT cells, invariant natural killer T cells and macrophages also become idealized T cell sources in terms of Universal CAR-T (UCAR-T) cell therapeutics. In addition, studies demonstrated that more balanced CD4 +/CD8 + T cell ratio and eliminating monocytes during leukapheresis have a positive influence on CAR-T cell functioning, whereas T cells with higher exhaustion markers expression hampers anti-tumor ability of CAR-T cells after infusion. To avoid application of such T cells or mitigate the impact using immune checkpoint inhibitors is of great importance.
